Randomized trial demonstrates startup viability audits through a multi-stage framework, indicating improved evaluations and reduced risks.
Early-stage software startup failure is predominantly caused by ungrounded market hypotheses, premature product synthesis, and sycophantic validation (a common failure mode in Large Language Model (LLM) agents where systems appease user assumptions rather than challenging operational vulnerabilities). In this white paper, we introduce AVERT (Adversarial Venture Evaluation and Risk-Sensitive Transition Framework), an autonomous, multi-stage gated state-machine architecture designed to conduct cold-blooded, adversarial viability audits of startup concepts. We provide an exhaustive mathematical formalization of the 5 Master Stages (Discovery, Viability, Timing/Moats, Virality/TTV, and Buildspec Scoping), detail the complete parameter taxonomy governing state transitions (including the Composite Wedge Score CWS >= 6.5, First-Day Conversion Rate FDCR >= 12.5%, and 50/50 Symbiotic Grounding Standard), and formalize the Resync & Restart Strategy (RSRS) cascade protocol. Furthermore, we demonstrate how ZipAI subagent context isolation and Defuddle DOM noise reduction achieve an 89.8% reduction in token consumption while enforcing strict human-in-the-loop deliberation gates before code artifact generation. Key Architectural Contributions:1. Adversarial Persona Triad: Replaces sycophantic LLM roleplay with 3 non-cooperative evaluation roles (Institutional VC Partner, 7 Powers Growth Architect, Red Team Auditor).2. Mathematical State Gating: Enforces quantitative indicator thresholds (CWS >= 6.5, FDCR >= 12.5%, SDGI) for step-function state transitions.3. RSRS Pivot Protocol & Convergence Guarantee: Formulates the Resync & Restart Strategy cascade reset operator, supported by Theorem 5.1 proving bounded finite convergence.4. Subagent Context Isolation & Token Engineering: Achieves 89.8% token reduction via context isolation and Defuddle DOM noise reduction.
No takes yet. Share an insight, caveat, or question.
Samagra Singh (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: